ERBB3 and ovarian cancer: Torka et al. [36] discovered that small interfering RNA-induced or pharmacological inhibition of AXL increased human epidermal growth factor receptor 3 (HER3) expression and phosphorylation as a compensatory mechanism for the overexpression of AXL, thereby increasing cell viability in MDA-MB-231 (breast) and Ovcar8 (ovarian) cancer cells.